Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China

References

• WHO. Obesity: preventing and managing the global epidemic. Technical Report Series 894; 2000.
   Google Scholar
• Skibola CF, Holly EA, Forrest MS, et al. Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2004;13:779–786.
   PubMed Web of Science ®Google Scholar
• Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12:13–21.
   PubMed Web of Science ®Google Scholar
• Pan SY, Mao Y, Ugnat AM. Canadian Cancer Registries Epidemiology Research Group. Physical activity, obesity, energy intake, and the risk of non-Hodgkin’s lymphoma: a population-based case-control study. Am J Epidemiol. 2005;162:1162–1173.
   PubMed Web of Science ®Google Scholar
• Expert Consultation WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
   PubMed Web of Science ®Google Scholar
• Hong F, Habermann TM, Gordon LI, et al. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol.2014;25:669–674.
   PubMed Web of Science ®Google Scholar
• Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph consortium. Int J Cancer. 2008;122:2062–2070.
   PubMed Web of Science ®Google Scholar
• Chang E, Hjalgrim T, Ekström Smedby HK, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005;97:210–218.
   PubMed Web of Science ®Google Scholar
• Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30:3217–3222.
   PubMed Web of Science ®Google Scholar
• Weiss L ,Melchardt T, Habringer S, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol.2014;25:171–176.
   PubMed Web of Science ®Google Scholar
• Jones JA, Fayad LE, Elting LS, et al. Body mass index and outcomes in patients receiving chemo therapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51:1649–1657.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Janney CA, Vachon CM, et al. Anthropometric characteristics, physical activity, and risk of non-Hodgkin’s lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol. 2002;156:527–535.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Yoon DH, Suh C, et al. Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified. Ann Hematol. 2015;94:1655–1665.
   PubMed Web of Science ®Google Scholar
• Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90:77–89.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Lim U, Gayles T, Katki HA, et al. Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Res. 2007;67:5569–5574.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–765.
   PubMed Web of Science ®Google Scholar
• Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin’s lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol. 2005;16:1413–1424.
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277–283.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321–1327.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007 Oct 20;25:4707–4713.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.
   PubMed Web of Science ®Google Scholar
• Iannone F, Lapadula G. Obesity and inflammation targets for OA therapy. Curr Drug Targets. 2010;11:586–598.
   PubMed Web of Science ®Google Scholar
• Geyer SM, Morton LM, Habermann TM, et al. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer. 2010;116:2993–3000.
   PubMed Web of Science ®Google Scholar
• Leo QJN, Ollberding NJ, Wilkens LR, et al. Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the multiethnic cohort study. Cancer Causes Control. 2014;25:1449–1459.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar